05:18 PM EDT, 07/09/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Tuesday that the US Food and Drug Administration approved Zoryve to treat mild to moderate atopic dermatitis in adults and pediatric patients six years and older.

The supplemental new drug application for Zoryve was supported by results from three phase three clinical studies including Intengument-1 and Intengument-2, according to the company.

Arcutis said it plans to make Zoryve cream 0.15% widely available by the end of the month.

Zoryve is already approved for the treatment of seborrheic dermatitis and plaque psoriasis.

Price: 10.12, Change: +0.10, Percent Change: +1.00